Latest News:
- Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany
- Deferasirox Accord: A new generic of Exjade recommended for approval by the EMA
- FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
- Thalassaemia Month of Banyumas 2019 -„Banyumas Goes to Zero Growth of Thalassaemia 2023“
- The Emirates Thalassaemia Society launches the 12th edition of the “What is Thalassaemia?“competition
TIF
